Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis

by White, N M A, Masui, O, Newsted, D, Scorilas, A, Romaschin, A D, Bjarnason, G A, Siu, K W M, Yousef, G M
Published 2014

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215

by White, N M A, Khella, H W Z, Grigull, J, Adzovic, S, Youssef, Y M, Honey, R J, Stewart, R, Pace, K T, Bjarnason, G A, Jewett, M A S, Evans, A J, Gabril, M, Yousef, G M
Published 2011

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

by Ko, J J, Choueiri, T K, Rini, B I, Lee, J-L, Kroeger, N, Srinivas, S, Harshman, L C, Knox, J J, Bjarnason, G A, MacKenzie, M J, Wood, L, Vaishampayan, U N, Agarwal, N, Pal, S K, Tan, M-H, Rha, S Y, Yuasa, T, Donskov, F, Bamias, A, Heng, D Y C
Published 2014

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

by Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R
Published 2015